---
schema_version: "secwatch.filing_event.v1"
accession: "0001021771-25-000092"
form_type: "8-K"
ticker: "BRTX"
cik: "0001505497"
company_name: "BioRestorative Therapies, Inc."
filed_at: "2025-06-13T23:59:59+00:00"
generated_at: "2026-05-19T08:04:35.282735+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# BioRestorative presents Phase 2 data for BRTX-100: >50% improvement in pain/function in >70% of subjects

## Summary
- Preliminary blinded data from 36 subjects in Phase 2 trial of BRTX-100 for chronic lumbar disc disease presented at ISSCR 2025.
- Over 74% of subjects showed >50% improvement in function (ODI) by week 52; over 72% had >50% pain reduction (VAS).
- No serious adverse events or dose-limiting toxicities reported between 26 and 104 weeks at target dose of 40 million cells.
- Number of evaluated subjects increased from 15 to 36 since last update; FDA requires >30% improvement thresholds.
- CEO Lance Alstodt expressed confidence BRTX-100 can meet or exceed FDA thresholds for function and pain.

## SEC filing metadata
- accession: 0001021771-25-000092
- form_type: 8-K
- ticker: BRTX
- cik: 0001505497
- company_name: BioRestorative Therapies, Inc.
- filed_at: 2025-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1505497/000102177125000092/0001021771-25-000092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1505497/000102177125000092/brt8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001021771-25-000092
- JSON: https://secwatch.observer/filing/0001021771-25-000092.json
- Plain text: https://secwatch.observer/filing/0001021771-25-000092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.